Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients

This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kdFsXv
via IFTTT